Selecting the Right Treatment for your Patient with Severe Asthma

Released On
September 4, 2020

Expires On
September 3, 2021

Media Type

Completion Time
60 minutes

Allergy & Immunology


Scroll to the Bottom of this Information to Begin this Course

Provided by National Jewish Health.

This educational activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

This collaborative program was developed and presented by National Jewish Health with the Mount Sinai – National Jewish Health Respiratory Institute and the Jane and Leonard Korman Respiratory Institute - Jefferson Health and National Jewish Health. Together, these three organizations collaborate on research, clinical trials and other programs extending the impact they bring to patients and furthering the understanding of respiratory illness. The Respiratory Institute model of collaboration currently brings these three entities together, collectively referred to as “The Respiratory Institutes”.

The Respiratory Institutes provide specialized programs committed to multidisciplinary consultation, advanced diagnostics, and coordinated, collaborative care for the full range of lung conditions. With expert faculty working in sync, the Institutes are well-positioned to provide education to health care providers on best practices in respiratory medicine and improving overall care coordination.

Credit Available

  • Physicians — maximum of 1 AMA PRA Category 1 Credit(s)
  • Registered Nurses — 1 Contact Hours
  • ABIM Diplomates - maximum of 1 ABIM MOC medical knowledge points

All other health care professionals completing this course will be issued a statement of participation.


Target Audience

Pulmonologists, allergists, primary care physicians, pediatricians, nurse practitioners, physician assistants, and registered nurses

Program Overview

This program leverages the expertise of thought leaders to help busy physicians understand the nuances and clinical data to select the best treatment for patients with severe asthma. The decision should be based on multiple factors including biomarkers, endotype, comorbidities and patient-centered factors such as preferences and treatment administration.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Explain the mechanisms of action of biologic therapies and the targets for treatment in severe asthma
  • Execute strategies for diagnosing and differentiating uncontrolled and severe asthma
  • Select treatments based on endotypes, clinical biomarkers and patient-centered factors
  • Interpret the benefits and barriers to the different methods of administration of biologics with a patient-centered approach


Michael E. Wechsler, MD, MMSc

Michael E. Wechsler, MD, MMSc

Professor of Medicine
Director of The Cohen Family Asthma Institute
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO

Linda Rogers, MD

Linda Rogers, MD

Associate Professor of Medicine
Pulmonary, Critical Care and Sleep Medicine
Director, Clinical Asthma Program
Icahn School of Medicine at Mount Sinai
Mount Sinai -- National Jewish Health Respiratory Institute
New York, NY

Jessica Most, MD

Jessica Most, MD

Assistant Professor of Medicine
Pulmonary, Allergy and Critical Care
Director, Outpatient Services
Jefferson Health
Philadelphia, PA

Accreditation Statement

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Credit Designation

National Jewish Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider approved by the California Board of Registered Nursing, Provider Number 12724 for 1.0 nursing contact hours.

Disclosures of Conflicts of Interest

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, CME approval committee, and those in position to control the content of this activity disclose any relevant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties.

All CME educational activities sponsored by National Jewish Health are reviewed by our faculty CME committee to ensure a balanced and evidence-based presentation. Any potential conflict of interest among program faculty has been identified and resolved according to ACCME guidelines.

Faculty Disclosures

Jessica Most, MD discloses she is a speaker for Genentech and a consultant for AstraZeneca.

Linda Rogers, MD discloses she is an investigator for Sema 4 and on an advisory board for AstraZeneca and Novartis.

Michael E. Wechsler, MD, MMSc discloses he is an investigator for AstraZeneca, Sanofi, and Teva and a consultant for AstraZeneca, Sanofi, Teva, Regeneron, GlaxoSmithKline, Novartis, Genentech, Sentien, Equillium, and Cohero.

Planners and Reviewers Disclosures

Deborah A. Fending, RN, BSN, AE-C has no financial relationships to disclose.
Andrea Harshman, MHA, CHCP, CMP-HC has no financial relationships to disclose.
Laurie Manka, MD has no financial relationships to disclose.
Harold Nelson, MD discloses he is on the data safety monitoring board for AstraZeneca.
Lauren Rieck has no financial relationships to disclose.
Patient in video has no financial relationships to disclose.

Instructions for Participation and Credit

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants.
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the learning objectives and disclosures
  2. Study the educational activity
  3. Complete the post-test and the evaluation form
If you successfully complete the post-test (score of 70% or higher), your certificate will be made available immediately. If you have any question relating to the accreditation of this activity, please contact:

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.

Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.


National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.

Privacy Policy

The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME).

We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME programming.

If you decide to register for an Internet CME program, we will collect personal information that you voluntarily share with us. We will only use this information to notify you of future National Jewish Health CME activities.